Implanet PEG
The PEG Ratio (Price/Earnings-to-Growth) of Implanet (ALIMP.PA) as of Jul 26, 2026 is -0.07.
Get this data via API
Financial Data API
PEG
-0.07
Last updated:
PEG Ratio (Price/Earnings-to-Growth) of Implanet is 2026 -0.07 . PEG Ratio (Price/Earnings-to-Growth) of Implanet was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Implanet Stock analysis
What does Implanet do? Implanet SA is a French company that specializes in the manufacture and distribution of innovative medical products. The company was founded in 2007 by Ludovic Lastennet and Rémi Boyer and is headquartered in Bordeaux, France.
Implanet's business model focuses on the development, production, and marketing of medical implants and instruments to support orthopedic surgeries. The company works closely with leading surgeons and healthcare facilities to find the ideal solution for patient needs.
One of Implanet's main areas of expertise is the spine. The company develops various implantable products for the treatment of degenerative diseases such as scoliosis. Another important area for Implanet is orthopedics, where the company develops solutions for joint problems like knee or hip replacements. The company also creates customized implants tailored to each individual patient for maximum accuracy and effectiveness.
A key aspect of Implanet's business model is adapting its products to meet customer requirements. The company collaborates closely with its customers to meet their specific needs and deliver the best possible solution. Implanet is committed to developing innovative solutions that align with surgeons' capabilities and cater to their needs.
Implanet maintains partnerships and distribution agreements worldwide to sell its products and achieve market gains. The company distributes its products in the US, Europe, and Asia. To further expand its presence in these markets, Implanet collaborates closely with healthcare organizations and surgeons to ensure its products remain up-to-date and meet customer needs.
Implanet strives to develop innovative solutions that revolutionize orthopedics and spine care. The company has already achieved significant success in the past with its Jazz technology, which serves as an excellent example of how the company operates in a customer-oriented and innovative manner. The Jazz technology is an implant designed for scoliosis treatment and is customized to each individual patient.
Overall, Implanet has developed an innovative and customer-oriented business model that focuses on continuous product development and collaboration with surgeons and healthcare organizations. With a strong presence in the global market and a range of innovative products, the company positions itself as one of the leading providers in the field of spine care and orthopedics. Implanet is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Implanet stock
PEG Ratio (Price/Earnings-to-Growth) of Implanet is -0.07 in 2026.
Access this data via the Eulerpool API
Valuation — Implanet
All Key Metrics — Implanet
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth